Results 51 to 60 of about 22,174 (220)

Trends in hospitalizations for vaccine‐preventable diseases in the United States from 2014 to 2024

Journal of Hospital Medicine, EarlyView.
Abstract Background and Objectives Vaccination rates have declined in recent years, resulting in outbreaks of vaccine‐preventable diseases (VPDs) among children. We aimed to evaluate VPD hospitalization rates from 2014 to 2024 and to report associated trends in outcomes including intensive care utilization, mortality, readmissions, and costs.
Nathan M. Money, Erin Sullivan, Hannah Rector, Corrie E. McDaniel, Jessica L. Markham, Mersine A. Bryan   +5 more
wiley   +1 more source

Comparison of incidence of medically-attended varicella and hospitalization for complicated varicella in Ontario children among pre-varicella vaccine, privately-available varicella vaccine and varicella vaccine program periods.

, 2015
Notes: 1. For varicella-associated SSTI, privately-available varicella vaccine period consists of FY 2002–2003.Comparison of incidence of medically-attended varicella and hospitalization for complicated varicella in Ontario children among pre-varicella ...
Jun Wang (5906), Shelley L. Deeks (138881), Anne E. Wormsbecker (770340), Jeffrey C. Kwong (138873), Natasha S. Crowcroft (138954), Chi Yon Seo (770341), Laura C. Rosella (105944)   +6 more
core   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Hypersensitivity to Excipients in Drugs: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT Drugs contain active pharmaceutical ingredients and excipients, compounds which enhance the pharmacokinetics, stability and palatability of the pharmaceutical formulation. While most drug hypersensitivity reactions (DHR) are caused by active ingredients, excipients may also be involved.
Lene H. Garvey, Knut Brockow, Annick Barbaud, Charlotte G. Mortz, Gianfranco Calogiuri, Asli Gelincik, Osman O. Yeğit, Alla Nakonechna, Annette Wagner, Rik Schrijvers, Toon Ieven   +10 more
wiley   +1 more source

Modelling Impact of Different Varicella Immunisation Strategies Upon Introduction in the Swedish National Programme

Acta Paediatrica, EarlyView.
ABSTRACT Aim Countries with varicella immunisation programmes have seen major reductions in disease burden. While two‐dose schedules are now universally adopted, dosing ages vary, and some countries initially include catch‐up vaccination of older children to speed impact. This modelling study assessed three two‐dose schedules in the Swedish setting (1)
Gianpaolo Scalia Tomba, Frida Kasteng, Annika Ersson, Sören Andersson, Emma Appelqvist, Marie Nordahl, Kari Johansen   +6 more
wiley   +1 more source

Varicella vaccine [PDF]

Reactions Weekly, 2003
In Canada, varicella vaccine is recommended but its uptake has been low. In contrast to most other recommended paediatric vaccines, this one is not currently provided free of charge in all provinces and territories in Canada.To evaluate the rate of health care provider offer of varicella vaccine to parents and the most important determinants of ...
François P, de Courval, Gaston, De Serres, Bernard, Duval   +2 more
openaire   +3 more sources

Median (IQR) age of varicella cases by clinical setting in the pre-varicella vaccine period, the privately-available varicella vaccine period and varicella vaccine program period.

, 2015
Notes: 1. SSTI (Skin and soft tissue infection). 2. ICU (Intensive care unit). 3. For varicella-associated SSTI, privately-available varicella vaccine period consists of FY 2002–2003.Median (IQR) age of varicella cases by clinical setting in the pre ...
Jun Wang (5906), Shelley L. Deeks (138881), Anne E. Wormsbecker (770340), Jeffrey C. Kwong (138873), Natasha S. Crowcroft (138954), Chi Yon Seo (770341), Laura C. Rosella (105944)   +6 more
core   +1 more source

Rationale for Recommending Varicella Vaccination Into the Swedish National Immunisation Programme

Acta Paediatrica, EarlyView.
ABSTRACT Aim Under Swedish law, a vaccination may be included in the National Immunisation Programme (NIP) if it effectively prevents transmission in the population, is cost‐effective and aligns with ethical and humanitarian principles. The Public Health Agency of Sweden (PHAS) evaluated these criteria for introducing varicella vaccination. Methods The
Annika Ersson, Kari Johansen, Sören Andersson   +2 more
wiley   +1 more source

Children with breakthrough varicella infection requiring hospitalization in Turkey (VARICOMP Study 2008-2013)

, 2015
Introduction: Varicella in previously immunized individuals, known as "breakthrough varicella". While the majority of breakthrough cases are mild, some may be severe, requiring hospitalization in previously healthy children or children with an underlying
Siraneci R., Hatipoglu S., Kara A., Parlakay A., VARICOMP Study Group, Elevli M., Oncel S., Karli A., Apa H., Somer A., Bal B., Belet N., Ince E., Dinleyici E.C., Devrim I., Metin O., Akaslan A., Hatipoglu N., Uygur-Kulcu N., Kocabas E., Ozdemir H., Alhan E., Kilic O., Say A., Gulhan B., Kuzdan C., Nuhoglu C., Yasa O., Tapisiz A., Ciftci E., Sag C., Goksugur Y., Hacimustafaoglu M., Kuyucu N., Velipasalioglu S., Kondolot M., Yilmaz-Ciftdogan D., Baktir A., Guler E., Aygun D., Karbuz A., Ozen M., Akarsu S., Dalgic N., Celebi S., Bayram S.N., Turel O., Sensoy G., Kurugol Z., Tas M.A., Tanir G., Emiroglu M., Ceyhan M., Arisoy E.S., Tezer H., Akin F.   +55 more
core   +2 more sources

A fresh look at varicella vaccination

Human Vaccines & Immunotherapeutics
The varicella vaccine is a live attenuated varicella zoster virus (VZV), first produced by Michiaki Takahashi (1974). Subsequent development of the fluorescent antibody to VZV membrane antigen test (FAMA), an immune correlate, permitted vaccine efficacy ...
Anne A. Gershon, Michael D. Gershon
doaj   +1 more source